Skip to main content
. 2022 Apr 7;2022(4):CD007216. doi: 10.1002/14651858.CD007216.pub2

JPRN‐UMIN000004201.

Methods Study design: RCT
Participants 50
Interventions Remission maintenance therapy group: for 48 weeks with immunomodulator from 2 weeks to 4 weeks following remission induction with tacrolimus
No remission maintenance therapy group: with immunomodulator following remission induction with tacrolimus
Outcomes Remission rate 48 weeks after the administration of tacrolimus
Notes Contact: Kenji Watanabe at kenjiw@med.osaka‐cu.ac.jp